Maven Securities LTD Invests $2.24 Million in iShares Biotechnology ETF (NASDAQ:IBB)

Maven Securities LTD bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the 3rd quarter, Holdings Channel.com reports. The firm bought 15,363 shares of the financial services provider’s stock, valued at approximately $2,237,000.

A number of other institutional investors have also recently added to or reduced their stakes in IBB. Darwin Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF during the third quarter valued at approximately $29,000. Highline Wealth Partners LLC acquired a new stake in iShares Biotechnology ETF during the 3rd quarter valued at $30,000. Bbjs Financial Advisors LLC purchased a new stake in iShares Biotechnology ETF during the 2nd quarter worth $31,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF in the 3rd quarter worth $36,000. Finally, Voisard Asset Management Group Inc. purchased a new position in iShares Biotechnology ETF in the 3rd quarter valued at about $59,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Down 1.2 %

Shares of NASDAQ IBB opened at $140.00 on Wednesday. iShares Biotechnology ETF has a 1 year low of $121.84 and a 1 year high of $150.57. The stock’s 50-day simple moving average is $142.53 and its 200-day simple moving average is $142.14.

iShares Biotechnology ETF Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were issued a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.